首页> 外国专利> Pharmaceutical composition containing at least one Compound with activity of CB1 receptor, or a prodrug, tautomero or Salt thereof as active Component suitable for the prophylaxis and / or treatment of diseases related to the CB1 receptor in patients for Treatment and / or Youth

Pharmaceutical composition containing at least one Compound with activity of CB1 receptor, or a prodrug, tautomero or Salt thereof as active Component suitable for the prophylaxis and / or treatment of diseases related to the CB1 receptor in patients for Treatment and / or Youth

机译:包含至少一种具有CB1受体活性的化合物或其前药,互变异构体或盐作为活性成分的药物组合物,适合于预防和/或治疗与C / 1受体相关的疾病

摘要

For example, a new drug using 4.5-dihydro-1h-pirazol, combined with a lipasa inhibitor, is resistant to people receiving CB1 marijuana. These compounds and lipid inhibitors are particularly suitable for drug manufacturePeppermint for the treatment and / or prevention of obesity in adolescents and / or the treatment and / or prevention of drug-induced obesity in adolescents and adolescents. The favorite lipid inhibitor is Ortizpancyclines, ATL-962 and / or lipstatin. Compounds, combination and kit. Claim 2: Use according to claim 1 of a CB1 receptor antagonist compound of formula (1) or a prodrug, tautomer or salt thereof in combination with a lipase inhibitor compound in the manufacture of a medicament for treatment and 7th prophylaxis of obesity in adolescent and / or juvenile patients and / or for the treatment or prophylaxis of drug-induced obesity in adolescent patients: (as shown in formula (1) where R and R1 can be the same or different from each other and represent phenyl, thienyl or pyridyl unsubstituted or with 1, 2 or 3 Y substituents,C1-3 tar or Alcoy, hydroxi, halogen, trifluomethoxi, trifluoromethy, trifluoroxi, nitro, amino, mono-o dialquil (C1-2) - amine, mono-o dialquil (C1-2) - amido (c1-3) tar sulfur, dimethylamido (c1-3) alcoxi carbon, carboxyl, Sulfur trifluoride sulfur, cyanogen, amino acid, carbamate, sulfur and acetyl, or R and / or R1 for nafilo, R2 for H, hidrxi, c1-3 alcoxi, acetylene or acrylonitrile, and AA for one (I),Page: 1(III)(Iv) o (v)R4 and R5 represent h or c1-8 derivatives or non derivatives, respectively, or C3-8 cyclopropyl or R4 represents acetyl or dimethylamine, or 2,2,2-trifluoroethane or phenyl or pyridine, provided R5 represents h; R6 represents h or c1-3 without derivatives, BB represents sulfur or carbide, and R3 represents benzene, Phenyl, Tianjin or pyridine are not substituted, or there may be 1, 2 or 3 substitutes, and they may be the same or different,O R3 refers to c1-8 dendrite or non dendrite asphalt, or C3-8 cyclododecane or R3 refers to nafilo. 13. Claim 3: use a formula compound (1) according to the requirements of item 2, which is characterized by R as 4-chlorophenyl, R1 as phenyl, R2 as h, AA as R4 as h, R5 as methyl, BB as sulfur, R3 as 4-chlorophenyl and its salts.
机译:例如,使用4.5-二氢-1h-吡唑和一种脂肪酶抑制剂的新药对接受CB1大麻的人具有抵抗力。这些化合物和脂质抑制剂特别适合于药物制造薄荷糖,用于治疗和/或预防青少年的肥胖症和/或治疗和/或预防药物引起的肥胖症的青少年。最受欢迎的脂质抑制剂是Ortizpancyclines,ATL-962和/或Lipsatin。化合物,组合物和试剂盒。权利要求2:根据权利要求1的式(1)的CB1受体拮抗剂化合物或其前药,互变异构体或盐与脂肪酶抑制剂化合物的组合在制备用于治疗和第七种预防青少年肥胖症的药物中的用途。 /或青少年患者和/或用于治疗或预防青少年患者的药物性肥胖:(如式(1)所示,其中R和R1可以相同或不同,代表未取代的苯基,噻吩基或吡啶基或具有1个,2个或3个Y取代基,C1-3焦油或铝,羟基,羟基,卤素,三氟甲基,三氟甲基,三氟,硝基,氨基,单-邻二烯基(C1-2)-胺,单-邻二烯基(C1- 2)-酰胺基(c1-3)焦油硫,二甲基酰胺基(c1-3)醇碳,羧基,三氟化硫,氰,氨基酸,氨基甲酸酯,硫和乙酰基,R和/或R1代表纳菲罗,R2代表H ,hidrxi,c1-3醇,乙炔或丙烯腈和AA(I),页面:1(III)(Iv)o(v)R4和R5分别代表h或c1-8衍生物或非衍生物,或C3-8环丙基或R4代表乙酰基或二甲胺,或2,2,2-三氟乙烷或苯基或吡啶,R5代表h; R6代表h或c1-3,不带衍生物,BB代表硫或碳化物,R3代表苯,苯基,天津或吡啶未被取代,或可以有1、2或3个取代基,它们可以相同或不同, O R3表示c1-8树枝状或非树枝状沥青,或C3-8环十二烷或R3表示Nafilo。 13.权利要求3:根据第2项的要求使用式化合物(1),其特征在于R为4-氯苯基,R1为苯基,R2为h,AA为R4为h,R5为甲基,BB为。硫,R 3为4-氯苯基及其盐。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号